Abstract
Antibiotic treatment for Pseudomonas aeruginosa (Pa) in cystic fibrosis is limited in efficacy and may lead to multi‐drug resistance (MDR). Alternatives such as bacteriophages are being ex-plored but well designed, and controlled trials are crucial. The rational selection of patients with bacteriophage susceptible infections is required for both safety and efficacy monitoring. We ques-tioned whether bacteriophage susceptibility profiles were constant or variable over time, variability having been reported with antibiotics. Serial Pa isolates (n = 102) from 24 chronically infected cystic fibrosis (CF) patients over one year were investigated with plaque and antibiotic disc diffusion as-says. Variable number tandem repeat (VNTR) analysis identified those patients with >1 isolate. A median (range) of 4 (3–6) isolates/patient were studied. Twenty‐one (87.5%) individuals had a single VNTR type; three (12.5%) had two VNTR types at different times. Seventy‐five percent of isolates were sensitive to bacteriophage at ≥ 1 concentration; 50% of isolates were antibiotic multidrug re-sistant. Serial isolates, even when representing a single VNTR type, varied in sensitivity to both bacteriophages and antibiotics. The rates of sensitivity to bacteriophage supports the development of this therapy; however, the variability in response has implications for the selection of patients in future trials which must be on the basis of current, not past, isolate testing.
Original language | English |
---|---|
Article number | 660 |
Pages (from-to) | 1-12 |
Number of pages | 12 |
Journal | Microorganisms |
Volume | 9 |
Issue number | 3 |
DOIs | |
Publication status | Published - Mar 2021 |
Bibliographical note
Publisher Copyright:© 2021 by the authors. Licensee MDPI, Basel, Switzerland.
Keywords
- Adjunctive therapy
- Antimicrobial resistance
- Bacteriophage
- Cystic fibrosis
- Novel antimicrobials
- Pseudomonas aeruginosa
- Pulmonary infection